Nucryst appoints interim CEO
This article was originally published in Scrip
Nucryst Pharmaceuticals (US) has appointed David Holtz interim president and chief executive officer, and Neil Carragher chairman. Mr Holtz, who remains CFO, succeeds Thomas Gardner, who was chairman, president and CEO. Mr Carragher was formerly Nucryst's lead director.
You may also be interested in...
Firm supplying all-in-one multivitamin blends rather than packs of multiple pills has four-member advisory board including digital marketing and consumer product marketing specialists and a health care strategist.
UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.
Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.